Download PDF
CC BY-NC-ND 4.0 · J Neuroanaesth Crit Care 2016; 03(04): S29-S34
DOI: 10.4103/2348-0548.174732
Conference Proceeding
Thieme Medical and Scientific Publishers Private Ltd.

Deep vein thrombosis in neurocritical care

Smita Sharma
1   Bombay Hospital and Medical Research Centre, Mumbai, Maharashtra, India
› Author Affiliations
Further Information

Publication History

Publication Date:
05 May 2018 (online)

   Permissions and Reprints

INTRODUCTION

Deep vein thrombosis (DVT) is a common complication in critically ill neurological patients and can lead to thromboembolic episodes, which can in turn lead to morbidity and can even be fatal. Although there is paucity of data on the actual incidence of venous thromboembolism (VTE) as a cause of death in Indian patients, recent evidence suggests that DVT occurs as frequently among Asians as it does among Caucasians.[1] More importantly, it is a preventable complication, and hence there is a need for greater awareness of thromboprophylaxis among treating neurophysicians and neurosurgeons. There is also a great need for neurosurgeons to understand the role of anticoagulants when the benefits outweigh the risk. Despite our better understanding and the growing body of evidence regarding the beneficial role of thromboprophylaxis among medical and neurological Intensive Care Unit (ICU) patients, there is a general gap between knowledge and actual practice.

 

  • REFERENCES

  • 1 Prasannan S, Chin LN, Gul YA. Venous thromboembolic disease prophylaxis among general surgeons in Malaysia. Asian J Surg 2005; 28: 125-30
    CrossrefPubMedGoogle Scholar
  • 2 Swann KW, Black PM. Deep vein thrombosis and pulmonary emboli in neurosurgical patients: A review. J Neurosurg 1984; 61: 1055-62
    CrossrefPubMedGoogle Scholar
  • 3 Henwood PC, Kennedy TM, Thomson L, Galanis T, Tzanis GL, Merli GJ. et al. The incidence of deep vein thrombosis detected by routine surveillance ultrasound in neurosurgery patients receiving dual modality prophylaxis. J Thromb Thrombolysis 2011; 32: 209-14
    CrossrefPubMedGoogle Scholar
  • 4 Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR. et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133 (Suppl. 06) Suppl 381S-453S
    CrossrefPubMedGoogle Scholar
  • 5 Crowther MA, Cook DJ, Griffith LE, Meade M, Hanna S, Rabbat C. et al. Neither baseline tests of molecular hypercoagulability nor D-dimer levels predict deep venous thrombosis in critically ill medical-surgical patients. Intensive Care Med 2005; 31: 48-55
    CrossrefPubMedGoogle Scholar
  • 6 Tanislav C, Puille M, Pabst W, Reichenberger F, Grebe M, Nedelmann M. et al. High frequency of silent pulmonary embolism in patients with cryptogenic stroke and patent foramen ovale. Stroke 2011; 42: 822-4
    CrossrefPubMedGoogle Scholar
  • 7 Boström S, Holmgren E, Jonsson O, Lindberg S, Lindström B, Winsö I. et al. Post-operative thromboembolism in neurosurgery. A study on the prophylactic effect of calf muscle stimulation plus dextran compared to low-dose heparin. Acta Neurochir (Wien) 1986; 80: 83-9
    CrossrefPubMedGoogle Scholar
  • 8 Quevedo JF, Buckner JC, Schmidt JL, Dinapoli RP, O'Fallon JR. Thromboembolism in patients with high-grade glioma. Mayo Clin Proc 1994; 69: 329-32
    CrossrefPubMedGoogle Scholar
  • 9 Sawaya R, Ramo OJ, Glas-Greenwalt P, Wu SZ. Plasma fibrinolytic profile in patients with brain tumors. Thromb Haemost 1991; 65: 15-9
    Article in Thieme ConnectPubMedGoogle Scholar
  • 10 Sawaya R, Zuccarello M, Elkalliny M, Nishiyama H. Postoperative venous thromboembolism and brain tumors: Part I. Clinical profile. J Neurooncol 1992; 14: 119-25
    PubMedGoogle Scholar
  • 11 Moore RA, Adel N, Riedel E, Bhutani M, Feldman DR, Tabbara NE. et al. High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: A large retrospective analysis. J Clin Oncol 2011; 29: 3466-73
    CrossrefPubMedGoogle Scholar
  • 12 Muchmore JH, Dunlap JN, Culicchia F, Kerstein MD. Deep vein thrombophlebitis and pulmonary embolism in patients with malignant gliomas. South Med J 1989; 82: 1352-6
    CrossrefPubMedGoogle Scholar
  • 13 Hamilton MG, Hull RD, Pineo GF. Prophylaxis of venous thromboembolism in brain tumor patients. J Neurooncol 1994; 22: 111-26
    CrossrefPubMedGoogle Scholar
  • 14 Hirsh J, Gallus AS. 125-I-labeled fibrinogen scanning. Use in the diagnosis of venous thrombosis. JAMA 1975; 233: 970-3
    CrossrefPubMedGoogle Scholar
  • 15 Fard MN, Mostaan M, Anaraki MR. Utility of lower-extremity duplex sonography in patients with venous thromboembolism. J Clin Ultrasound 2001; 29: 92-8
    CrossrefPubMedGoogle Scholar
  • 16 Rossi R, Agnelli G. Current role of venography in the diagnosis of deep-vein thrombosis. Minerva Cardioangiol 1998; 46: 507-14
    PubMedGoogle Scholar
  • 17 Archie Jr. JP, McDaniel DN, Dean VH, Jester JE, Hall DC. Doppler ultrasound evaluation for lower extremity deep venous thrombosis in a community hospital. N C Med J 1989; 50: 457-60
    PubMedGoogle Scholar
  • 18 Kamphuisen PW, Agnelli G, Sebastianelli M. Prevention of venous thromboembolism after acute ischemic stroke. J Thromb Haemost 2005; 3: 1187-94
    CrossrefPubMedGoogle Scholar
  • 19 Macdonald RL, Amidei C, Lin G, Munshi I, Baron J, Weir BK. et al. Safety of perioperative subcutaneous heparin for prophylaxis of venous thromboembolism in patients undergoing craniotomy. Neurosurgery 1999; 45: 245-51
    CrossrefPubMedGoogle Scholar
  • 20 Turpie AG, Lensing AW, Fuji T, Boyle DA. Pharmacokinetic and clinical data supporting the use of fondaparinux 1.5 mg once daily in the prevention of venous thromboembolism in renally impaired patients. Blood Coagul Fibrinolysis 2009; 20: 114-21
    CrossrefPubMedGoogle Scholar
  • 21 King AE, Szarlej DK, Rincon F. Dabigatran-associated intracranial hemorrhage: Literature review and institutional experience. Neurohospitalist 2015; 5: 234-44
    PubMedGoogle Scholar
  • 22 Norwood SH, Berne JD, Rowe SA, Villarreal DH, Ledlie JT. Early venous thromboembolism prophylaxis with enoxaparin in patients with blunt traumatic brain injury. J Trauma 2008; 65: 1021-6
    CrossrefPubMedGoogle Scholar
  • 23 Reiff DA, Haricharan RN, Bullington NM, Griffin RL, McGwin Jr. G, Rue 3rd LW. Traumatic brain injury is associated with the development of deep vein thrombosis independent of pharmacological prophylaxis. J Trauma 2009; 66: 1436-40
    CrossrefPubMedGoogle Scholar
  • 24 Levy AS, Salottolo K, Bar-Or R, Offner P, Mains C, Sullivan M. et al. Pharmacologic thromboprophylaxis is a risk factor for hemorrhage progression in a subset of patients with traumatic brain injury. J Trauma 2010; 68: 886-94
    CrossrefPubMedGoogle Scholar
  • 25 Saadeh Y, Gohil K, Bill C, Smith C, Morrison C, Mosher B. et al. Chemical venous thromboembolic prophylaxis is safe and effective for patients with traumatic brain injury when started 24 hours after the absence of hemorrhage progression on head CT. J Trauma Acute Care Surg 2012; 73: 426-30
    CrossrefPubMedGoogle Scholar
  • 26 Phelan HA, Wolf SE, Norwood SH, Aldy K, Brakenridge SC, Eastman AL. et al. A randomized, double-blinded, placebo-controlled pilot trial of anticoagulation in low-risk traumatic brain injury: The delayed versus early enoxaparin prophylaxis I (DEEP I) study. J Trauma Acute Care Surg 2012; 73: 1434-41
    CrossrefPubMedGoogle Scholar
  • 27 Galanaud JP, Sevestre-Pietri MA, Bosson JL, Laroche JP, Righini M, Brisot D. et al. Comparative study on risk factors and early outcome of symptomatic distal versus proximal deep vein thrombosis: Results from the OPTIMEV study. Thromb Haemost 2009; 102: 493-500
    Article in Thieme ConnectPubMedGoogle Scholar
  • 28 Abdel-Aziz H, Dunham CM, Malik RJ, Hileman BM. Timing for deep vein thrombosis chemoprophylaxis in traumatic brain injury: An evidence-based review. Crit Care 2015; 19: 96
    CrossrefPubMedGoogle Scholar